Photo taken from Ruben Raychaudhuri/X
Jun 22, 2024, 05:04
Yüksel Ürün: Carboplatin plus docataxel for patients with biallelic HRR gene alterations in metastatic castration-resistant prostate cancer
Yüksel Ürün shared a post on X:
“The ABCD Trial shows promising results with carboplatin and docetaxel for patients with biallelic HRR gene alterations in metastatic castration-resistant prostate cancer:
- 69% achieved a PSA50 response.
- Median Progression-Free Survival (PFS): 8.4 months.
- Median Overall survival (OS): 1.42 years.
- Especially effective in BRCA1/2, PALB2 subgroup (PSA50 R: 78%).
- These findings suggest that carboplatin and docetaxel is a viable option, with further research ongoing.”
Source: Yüksel Ürün/X
Yüksel Ürün is a Medical Oncology professor at Ankara University School of Medicine in Turkey. His research focuses on genitourinary cancers, covering epidemiology, diagnosis, biomarkers, meta-analysis, and treatment outcomes. His dedication to patient care and research inspires positive change in the medical field.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 13, 2024, 19:25
Nov 13, 2024, 16:51
Nov 13, 2024, 16:49
Nov 13, 2024, 16:45
Nov 13, 2024, 16:25
Nov 13, 2024, 16:23
Nov 13, 2024, 16:08